Literature DB >> 30952223

Optimizing Actigraphic Estimation of Sleep Duration in Suspected Idiopathic Hypersomnia.

Jesse D Cook1,2, Sahand C Eftekari1, Lydia A Leavitt1, Michael L Prairie1, David T Plante1.   

Abstract

STUDY
OBJECTIVES: To determine the optimal Actiwatch 2 setting configuration for the estimation of total sleep time (TST) in persons with suspected idiopathic hypersomnia.
METHODS: Thirty-three patients with a diagnosis of idiopathic hypersomnia (28 female; mean age = 33.7 ± 10.5) underwent ad libitum polysomnography with concurrent use of the Actiwatch 2. Actiwatch 2 sleep-wake activity threshold (SWAT; Low, Medium, and High) and sleep immobility onset and offset (SIOO; 5, 10, 15, 20, 25, and 30 epoch) duration were modified during data processing. The resultant 18 unique setting combinations were subsequently evaluated using Bland-Altman and epoch comparison analyses to determine optimal settings relative to polysomnography.
RESULTS: Low SWAT + 25 Epoch SIOO displayed the least divergence from polysomnography (mean difference 3.4 minutes). Higher SWAT and lower SIOO increased sensitivity and accuracy, but at the expense of reducing specificity and the ability to accurately estimate TST.
CONCLUSIONS: These results demonstrate that actigraphic settings should be carefully considered when estimating sleep duration. The Low + 25 Epoch configuration is indicated as most optimal for estimating TST in persons with suspected idiopathic hypersomnia. COMMENTARY: A commentary on this article appears in this issue on page 539.
© 2019 American Academy of Sleep Medicine.

Entities:  

Keywords:  Actiwatch; actigraphy; hypersomnolence; idiopathic hypersomnia

Year:  2019        PMID: 30952223      PMCID: PMC6457505          DOI: 10.5664/jcsm.7722

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  25 in total

1.  Further validation of actigraphy for sleep studies.

Authors:  Luciane de Souza; Ana Amélia Benedito-Silva; Maria Laura Nogueira Pires; Dalva Poyares; Sergio Tufik; Helena Maria Calil
Journal:  Sleep       Date:  2003-02-01       Impact factor: 5.849

2.  IDS-C and IDS-sr: psychometric properties in depressed in-patients.

Authors:  E Corruble; J M Legrand; C Duret; G Charles; J D Guelfi
Journal:  J Affect Disord       Date:  1999-12       Impact factor: 4.839

3.  Evaluation of immobility time for sleep latency in actigraphy.

Authors:  Kyu Young Chae; Daniel F Kripke; J Steven Poceta; Farhad Shadan; Shazia M Jamil; John W Cronin; Lawrence E Kline
Journal:  Sleep Med       Date:  2008-12-21       Impact factor: 3.492

Review 4.  The role and validity of actigraphy in sleep medicine: an update.

Authors:  Avi Sadeh
Journal:  Sleep Med Rev       Date:  2011-01-14       Impact factor: 11.609

5.  Comparison of actigraphic, polysomnographic, and subjective assessment of sleep parameters in sleep-disordered patients.

Authors:  C A Kushida; A Chang; C Gadkary; C Guilleminault; O Carrillo; W C Dement
Journal:  Sleep Med       Date:  2001-09       Impact factor: 3.492

6.  The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation.

Authors:  M H Trivedi; A J Rush; H M Ibrahim; T J Carmody; M M Biggs; T Suppes; M L Crismon; K Shores-Wilson; M G Toprac; E B Dennehy; B Witte; T M Kashner
Journal:  Psychol Med       Date:  2004-01       Impact factor: 7.723

7.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

8.  Hypersomnolence and narcolepsy; a pragmatic diagnostic neurophysiological approach.

Authors:  P Boon; D Pevernagie; D Schrans
Journal:  Acta Neurol Belg       Date:  2002-03       Impact factor: 2.396

9.  The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.

Authors:  A John Rush; Madhukar H Trivedi; Hicham M Ibrahim; Thomas J Carmody; Bruce Arnow; Daniel N Klein; John C Markowitz; Philip T Ninan; Susan Kornstein; Rachel Manber; Michael E Thase; James H Kocsis; Martin B Keller
Journal:  Biol Psychiatry       Date:  2003-09-01       Impact factor: 13.382

Review 10.  The role of actigraphy in the study of sleep and circadian rhythms.

Authors:  Sonia Ancoli-Israel; Roger Cole; Cathy Alessi; Mark Chambers; William Moorcroft; Charles P Pollak
Journal:  Sleep       Date:  2003-05-01       Impact factor: 5.849

View more
  6 in total

1.  Are We There Yet? Getting Closer to Certainty in Idiopathic Hypersomnia Diagnosis.

Authors:  Lynn Marie Trotti
Journal:  J Clin Sleep Med       Date:  2019-04-15       Impact factor: 4.062

2.  The growing toolkit for evaluation of central disorders of hypersomnolence.

Authors:  David T Plante
Journal:  Sleep       Date:  2022-06-13       Impact factor: 6.313

Review 3.  Idiopathic Hypersomnia: Historical Account, Critical Review of Current Tests and Criteria, Diagnostic Evaluation in the Absence of Biological Markers and Robust Electrophysiological Diagnostic Criteria.

Authors:  Michel Billiard; Karel Sonka
Journal:  Nat Sci Sleep       Date:  2022-02-26

4.  The Psychomotor Vigilance Test as a measure of alertness and sleep inertia in people with central disorders of hypersomnolence.

Authors:  Lynn Marie Trotti; Prabhjyot Saini; Erin Bremer; Christianna Mariano; Danielle Moron; David B Rye; Donald L Bliwise
Journal:  J Clin Sleep Med       Date:  2022-05-01       Impact factor: 4.324

Review 5.  Central Disorders of Hypersomnolence.

Authors:  Lynn Marie Trotti
Journal:  Continuum (Minneap Minn)       Date:  2020-08

6.  To split or to lump? Classifying the central disorders of hypersomnolence.

Authors:  Rolf Fronczek; Isabelle Arnulf; Christian R Baumann; Kiran Maski; Fabio Pizza; Lynn Marie Trotti
Journal:  Sleep       Date:  2020-08-12       Impact factor: 5.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.